Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 12/20 | 0.37 |
| ▸ | METAP1 | P53582 | 3/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307691 | 0.93 | CCR1 (0.37) | CCR1METAP1SMOCYP2C19KCNH2 | |
| SCHEMBL4014907 | 0.90 | CCR1 (0.45) | CCR1METAP1CYP2C19KCNH2 | |
| SCHEMBL4306237 | 0.90 | CCR1 (0.42) | CCR1METAP1CYP2C19KCNH2 | |
| SCHEMBL4323120 | 0.82 | CCR1 (0.38) | CCR1METAP1SMO | |
| SCHEMBL4308366 | 0.79 | CCR1 (0.44) | CCR1CYP2C19KCNH2 | |
| SCHEMBL3463999 | 0.79 | CCR1 (0.61) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4013693 | 0.79 | CCR1 (0.45) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4016092 | 0.79 | CCR1 (0.42) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4017397 | 0.78 | CCR1 (0.45) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4018857 | 0.78 | CCR1 (0.47) | CCR1CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885METAP1 1007/4885SMO 3188/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | CCR1 1/4885METAP1 1007/4885SMO 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.